- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02252302
Exercise in Air Pollution and Lung Health in Asthmatics
28 september 2021 uppdaterad av: Michael Koehle, University of British Columbia
The Effects of Inhaled Beta-2-Agonists and Air Pollution on Lung Function and Athletic Capacity
When exposed to air pollution, the asthma symptoms are aggravated and lung function is impaired.
Due to high breathing rates and volumes, physically active individuals are at particular risk of lung health impairment due to the high breathing rates and volumes.
Greater doses of air pollutants reach deeper areas in the lungs where they can trigger asthma-symptoms.
When treating these symptoms with inhaled beta-2-agonists the airways widen even more, allowing the air pollutants to reach even deeper areas of the lung.
With this study the investigators investigate how inhaled beta-2-agonists affect athletic capacity and lung health in physically active asthmatics.
Studieöversikt
Status
Avslutad
Betingelser
Studietyp
Interventionell
Inskrivning (Förväntat)
20
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6T 1Z1
- University of British Columbia, Environmental Physiology Laboratory
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
19 år till 40 år (Vuxen)
Tar emot friska volontärer
Ja
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- mild-moderate asthmatics with controlled treatment (definition of "mild": percent fall index at eucapnic voluntary hyperpnea (EVH) test on screening day between 10-15%; "moderate": percent fall index at EVH test on screening day between 15 - 20%).
- men and non-pregnant women
Exclusion Criteria:
- any history of uncontrolled respiratory or cardiac disease
- pregnancy
- allergic reactions to lidocaine and salbutamol
- any recent infections or orthopaedic nasal issues/injuries that may interfere with the insertion of the catheter needed to assess expiratory flow limitation or work of breathing
- claustrophobia in small rooms, comparable to the air pollution chamber used for this study.
- English as a second language (ESL) - participants who are not able to understand the risk that may be associated with the participation in this study due to language difficulties after following the University of British Clinical Research Ethics Board Guidance Notes 13.2.1. (ESL participants will be given a consent form in the most appropriate language or an appropriate translator will be present during the initial consent process).
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Resting in diesel exhaust following salbutamol inhalation
Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of 400ug of salbutamol.
|
Study participants will sit on a chair for 60min.
This is to simulate physical resting condition.
Study participants will be exposed to 400ug of salbutamol prior to entering the air pollution chamber.
Participants will be exposed to PM2.5 of 300 μg/m3
|
Placebo-jämförare: Resting in diesel exhaust following placebo inhalation
Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of a placebo.
|
Study participants will sit on a chair for 60min.
This is to simulate physical resting condition.
Participants will be exposed to PM2.5 of 300 μg/m3
Study participants will inhale a placebo (placebo for salbutamol) prior to entering the air pollution chamber
|
Aktiv komparator: Cycling in diesel exhaust following salbutamol inhalation
Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of 400ug of salbutamol.
|
Study participants will be exposed to 400ug of salbutamol prior to entering the air pollution chamber.
Participants will be exposed to PM2.5 of 300 μg/m3
Study participants will exercise on a cycle ergometer for 45min.
Participants will start their 30-min long constant workload exercise test test 60-min after the drug intervention.
The exercise test will be set to a resistance of 50% of the maximal wattage that was reached on the graded exercise test on the screening day.
The cycling exercise intervention will follow the rest-intervention.
|
Placebo-jämförare: Cycling in diesel exhaust following placebo inhalation
Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of a placebo
|
Participants will be exposed to PM2.5 of 300 μg/m3
Study participants will inhale a placebo (placebo for salbutamol) prior to entering the air pollution chamber
Study participants will exercise on a cycle ergometer for 45min.
Participants will start their 30-min long constant workload exercise test test 60-min after the drug intervention.
The exercise test will be set to a resistance of 50% of the maximal wattage that was reached on the graded exercise test on the screening day.
The cycling exercise intervention will follow the rest-intervention.
|
Sham Comparator: Resting in filtered air following salbutamol inhalation
Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of 400ug of salbutamol.
|
Study participants will sit on a chair for 60min.
This is to simulate physical resting condition.
Participants will be breathing filtered air
|
Placebo-jämförare: Resting in filtered air following placebo inhalation
Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of a placebo.
|
Study participants will sit on a chair for 60min.
This is to simulate physical resting condition.
Participants will be breathing filtered air
|
Sham Comparator: Cycling in filtered air following salbutamol inhalation
Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of 400ug of salbutamol.
|
Study participants will be exposed to 400ug of salbutamol prior to entering the air pollution chamber.
Study participants will exercise on a cycle ergometer for 45min.
Participants will start their 30-min long constant workload exercise test test 60-min after the drug intervention.
The exercise test will be set to a resistance of 50% of the maximal wattage that was reached on the graded exercise test on the screening day.
The cycling exercise intervention will follow the rest-intervention.
Participants will be breathing filtered air
|
Placebo-jämförare: Cycling in filtered air following placebo inhalation
Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of a placebo
|
Study participants will inhale a placebo (placebo for salbutamol) prior to entering the air pollution chamber
Study participants will exercise on a cycle ergometer for 45min.
Participants will start their 30-min long constant workload exercise test test 60-min after the drug intervention.
The exercise test will be set to a resistance of 50% of the maximal wattage that was reached on the graded exercise test on the screening day.
The cycling exercise intervention will follow the rest-intervention.
Participants will be breathing filtered air
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Change in rating of perceived exertion for breathing, dyspnea
Tidsram: Difference in perceived dyspnea between salbutamol and placebo exposure as well as polluted air and filtered air. Dyspnea ratings will be collected every 2.5min for a duration of 45min during the exercise test.
|
Difference in perceived dyspnea between salbutamol and placebo exposure as well as polluted air and filtered air. Dyspnea ratings will be collected every 2.5min for a duration of 45min during the exercise test.
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Change in work of breathing (WOB) between filtered air and polluted air
Tidsram: work of breathing will be assessed every 2.5min for a time period of 45min during the exercise bout
|
work of breathing will be assessed every 2.5min for a time period of 45min during the exercise bout
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Change in spirometry (FEV1 and FVC) between filtered air and polluted air
Tidsram: Spirometry will be assessed at baseline and 45min after the start of the exercise bout.
|
Spirometry will be assessed at baseline and 45min after the start of the exercise bout.
|
|
Change in cognitive function
Tidsram: Cognitive function will be assessed at baseline (prior to entering the air pollution chamber) and 45 min after the start of the exercise intervention.
|
cognitive function will be assessed using the NIH toolbox tests and the brain derived neurotrophic factor (BDNF) blood serum measurements
|
Cognitive function will be assessed at baseline (prior to entering the air pollution chamber) and 45 min after the start of the exercise intervention.
|
Retinal Imaging
Tidsram: The retina will be imaged at baseline (prior to entering the air pollution chamber) and 20 min after the completion of the exercise intervention.
|
The blood vessels in the eye will be imaged using a camera.
|
The retina will be imaged at baseline (prior to entering the air pollution chamber) and 20 min after the completion of the exercise intervention.
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 maj 2015
Primärt slutförande (Faktisk)
1 augusti 2016
Avslutad studie (Faktisk)
1 maj 2021
Studieregistreringsdatum
Först inskickad
16 september 2014
Först inskickad som uppfyllde QC-kriterierna
29 september 2014
Första postat (Uppskatta)
30 september 2014
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
30 september 2021
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
28 september 2021
Senast verifierad
1 september 2021
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Läkemedels fysiologiska effekter
- Adrenerga medel
- Neurotransmittormedel
- Molekylära mekanismer för farmakologisk verkan
- Autonoma agenter
- Agenter från det perifera nervsystemet
- Adrenerga agonister
- Bronkdilaterande medel
- Anti-astmatiska medel
- Andningsorgan
- Reproduktionskontrollmedel
- Adrenerga beta-2-receptoragonister
- Adrenerga beta-agonister
- Tokolytiska medel
- Albuterol
Andra studie-ID-nummer
- H13-01079
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Luftförorening
-
Cairo UniversityAvslutadFekry VS Air-Q Intubating AirwaysEgypten
-
University of ZurichAvslutad
-
Dr.Mahak MehtaAvslutadProseal LMA vs Air-Q LMA vs Ambu AurGain LMA
-
University Hospital, MontpellierAix Marseille Université; LBM- Nanosecurity platform - CEA Grenoble; LR2N...AvslutadAir France Companys anställda som arbetar på Marseilles och Paris flygplatser (Flightline och administrativa anställda)Frankrike
-
Cardiochirurgia E.H.Avslutad